Monte Rosa Therapeutics Inc (GLUE) - Net Assets
Based on the latest financial reports, Monte Rosa Therapeutics Inc (GLUE) has net assets worth $521.92 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($736.43 Million) and total liabilities ($214.51 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible net worth ratio of Monte Rosa Therapeutics Inc to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $521.92 Million |
| % of Total Assets | 70.87% |
| Annual Growth Rate | N/A |
| 5-Year Change | -32.94% |
| 10-Year Change | N/A |
| Growth Volatility | 22.72 |
Monte Rosa Therapeutics Inc - Net Assets Trend (2019–2025)
This chart illustrates how Monte Rosa Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. See GLUE defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Monte Rosa Therapeutics Inc (2019–2025)
The table below shows the annual net assets of Monte Rosa Therapeutics Inc from 2019 to 2025. For live valuation and market cap data, see market value of Monte Rosa Therapeutics Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $233.06 Million | +4.54% |
| 2024-12-31 | $222.94 Million | +24.37% |
| 2023-12-31 | $179.25 Million | -33.96% |
| 2022-12-31 | $271.41 Million | -21.90% |
| 2021-12-31 | $347.51 Million | +813.17% |
| 2020-12-31 | $-48.73 Million | -301.12% |
| 2019-12-31 | $-12.15 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Monte Rosa Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 46501600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $7.00K | 0.00% |
| Other Comprehensive Income | $-3.83 Million | -1.64% |
| Other Components | $714.09 Million | 306.40% |
| Total Equity | $233.06 Million | 100.00% |
Monte Rosa Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Monte Rosa Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
China Railway Construction Corporation Limited
F:4FF
|
$1.55 Billion |
|
Galapagos N.V.
AS:GLPG
|
$1.55 Billion |
|
Shenzhen Heungkong Holding Co Ltd
SHG:600162
|
$1.55 Billion |
|
Realia
MC:RLIA
|
$1.55 Billion |
|
Friedrich Vorwerk Group SE
F:VH2
|
$1.55 Billion |
|
Flowers Foods Inc
NYSE:FLO
|
$1.55 Billion |
|
Three's Company Media Group Co Ltd
SHG:605168
|
$1.55 Billion |
|
Jiangsu Jujie Microfiber Technology
SHE:300819
|
$1.55 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Monte Rosa Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 222,936,000 to 233,056,000, a change of 10,120,000 (4.5%).
- Net loss of 38,626,000 reduced equity.
- Share repurchases of 357,000 reduced equity.
- New share issuances of 24,250,000 increased equity.
- Other comprehensive income decreased equity by 471,000.
- Other factors increased equity by 25,324,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-38.63 Million | -16.57% |
| Share Repurchases | $357.00K | -0.15% |
| Share Issuances | $24.25 Million | +10.41% |
| Other Comprehensive Income | $-471.00K | -0.2% |
| Other Changes | $25.32 Million | +10.87% |
| Total Change | $- | 4.54% |
Book Value vs Market Value Analysis
This analysis compares Monte Rosa Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.56x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-0.28 | $18.41 | x |
| 2020-12-31 | $-1.11 | $18.41 | x |
| 2021-12-31 | $7.47 | $18.41 | x |
| 2022-12-31 | $5.75 | $18.41 | x |
| 2023-12-31 | $3.49 | $18.41 | x |
| 2024-12-31 | $3.02 | $18.41 | x |
| 2025-12-31 | $2.81 | $18.41 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Monte Rosa Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -16.57%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -31.23%
- • Asset Turnover: 0.28x
- • Equity Multiplier: 1.93x
- Recent ROE (-16.57%) is above the historical average (-26.56%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-6.80 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-31.01 Million |
| 2021 | -21.28% | 0.00% | 0.00x | 1.05x | $-108.71 Million |
| 2022 | -39.98% | 0.00% | 0.00x | 1.26x | $-135.64 Million |
| 2023 | -75.51% | 0.00% | 0.00x | 1.69x | $-153.28 Million |
| 2024 | -32.61% | -96.14% | 0.17x | 1.97x | $-94.99 Million |
| 2025 | -16.57% | -31.23% | 0.28x | 1.93x | $-61.93 Million |
Industry Comparison
This section compares Monte Rosa Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Monte Rosa Therapeutics Inc (GLUE) | $521.92 Million | 0.00% | 0.41x | $1.55 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Monte Rosa Therapeutics Inc
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment… Read more